{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:24:31Z","timestamp":1773019471731,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T00:00:00Z","timestamp":1244419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Adverse drug reactions (ADRs) rank as the fifth leading cause of death in the western world. The nature and scope of these ADRs in children are not predictable based on post market surveillance reports that rely heavily on adult drug experience. The genotype\u2010specific approaches to therapy in childhood (GATC) national ADR network was established to identify specific ADRs and to improve drug safety through identification of predictive genomic biomarkers of drug risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>GATC set out to establish a national network of trained surveillance clinicians in pediatric hospitals across Canada. Surveillance clinicians identified, enrolled, and collected clinical data and biological samples from ADR cases and controls. Surveillance was targeted to three ADRs: anthracycline\u2010induced cardiotoxicity, cisplatin\u2010induced hearing impairment, and codeine\u2010induced mortality in breastfed infants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The initial surveillance site was established in September 2005, with 10 sites fully operational by 2008. In 3 years, GATC enrolled 1836 ADR cases and 13188 controls. Target numbers were achieved for anthracycline\u2010induced cardiotoxicity. Modified target numbers were nearly attained for cisplatin\u2010induced hearing impairment. Codeine\u2010induced infant mortality in a breastfed infant was discovered by GATC investigators. A case\u2013control study was subsequently conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>GATC has demonstrated a model of active and targeted surveillance that builds an important step toward the goal of personalized medicine for children. Effective communication, site\u2010specific solutions and long\u2010term sustainability across the network are critical to maintain participation and productivity. GATC may provide a framework of ADR surveillance that can be adapted by other countries and healthcare systems. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1772","type":"journal-article","created":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T07:49:52Z","timestamp":1244447392000},"page":"713-721","source":"Crossref","is-referenced-by-count":65,"title":["Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals"],"prefix":"10.1002","volume":"18","author":[{"given":"BC","family":"Carleton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RL","family":"Poole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MA","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JS","family":"Leeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Ghannadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CJD","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MS","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MR","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.15.1200"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915050-00003"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/phgs.4.3.231.22691"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1086-5802(16)31229-3"},{"issue":"6","key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/014107689108400612","article-title":"Spontaneous adverse drug reaction reporting vs event monitoring: a comparison","volume":"84","author":"Fletcher A","year":"1991","journal-title":"J R Soc Med"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427070-00004"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0475-9"},{"key":"e_1_2_1_9_2","unstructured":"Review of Food and Drug Administration's Handling of Adverse Drug Reaction Reports.Report No.: A\u201015\u201098\u201050001 Office of the Inspector General Department of Human and Health Services 14 December1999."},{"issue":"10","key":"e_1_2_1_10_2","first-page":"530","article-title":"Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study","volume":"36","author":"Gonzalez\u2010Martin G","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00943.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/phgs.4.3.331.22693"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540280039031"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.88.4.366"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0503-487"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","DOI":"10.1002\/047142613X","volume-title":"Pharmacogenomics: Social, Ethical, and Clinical Dimensions","author":"Rothstein M","year":"2003"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0603-590a"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199808000-00001"},{"key":"e_1_2_1_20_2","unstructured":"Slone Epidemiology Center.Patterns of medication use in the United States: a report from the Slone survey. Boston MA 2006.http:\/\/www. bu.edu\/slone\/SloneSurvey\/AnnualRpt\/SloneSurveyWebReport2006.pdf[Accessed 21 November 2007]."},{"key":"e_1_2_1_21_2","unstructured":"Health Canada.Important safety information on tylenol with codeine in nursing mothers and ultra\u2010rapid metabolizers of codeine.Health Canada Ottawa October2008.http:\/\/www.hc\u2010sc.gc.ca\/dhp\u2010mps\/alt_ formats\/hpfb\u2010dgpsa\/pdf\/medeff\/tylenol_codeine_hpc\u2010cps\u2010eng.pdf[Accessed 2 December 2008]."},{"key":"e_1_2_1_22_2","unstructured":"Food and Drug Administration.Warning on codeine use by nursing mothers.FDA Rockville August2007;http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01685.html[Accessed 27 February 2008]."},{"key":"e_1_2_1_23_2","unstructured":"Food and Drug Administration. 2007Safety alerts for drugs biologics medical devices and dietary supplements.FDA Rockville 2007;http:\/\/www.fda.gov\/medwatch\/safety\/2007\/safety07.htm[Accessed 7 December 2007]."},{"key":"e_1_2_1_24_2","unstructured":"Food and Drug Administration.FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events.FDA Rockville February2007.http:\/\/www.fda.gov\/bbs\/topics\/news\/2007\/new01568.html[Accessed 6 December 2007]."},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100099"},{"issue":"6","key":"e_1_2_1_26_2","first-page":"284","article-title":"The pediatric adverse drug reaction reporting system","volume":"4","author":"Carleton BC","year":"1999","journal-title":"J Pediatr Pharm Pract"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(01)80080-1"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69255-6"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/171516350613900610"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.157"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1772","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:47:00Z","timestamp":1699962420000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/pds.1772"],"URL":"https:\/\/doi.org\/10.1002\/pds.1772","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,8]]}}}